Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Longitudinal cognitive outcomes in two progressive supranuclear palsy clinical trials.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Trajectories of brain structure and function in young adult carriers of genetic frontotemporal dementia variants.

medRxiv : the preprint server for health sciences·2026
Same author

Clinical Associations of Cerebrospinal Fluid TMEM106B in Familial and Sporadic Frontotemporal Dementia.

JAMA neurology·2026
Same author

Development and validation of a harmonized memory score for multicenter Alzheimer's disease and related dementia research.

Alzheimer's research & therapy·2026
Same author

The BEYONDD Pilot Study: A Decentralized Community-Engaged Research Framework for Multimodal Characterization of Neurodegenerative Risk in a Multi-Ethnic, Midlife Cohort with Subjective Cognitive or Behavioral Complaints.

medRxiv : the preprint server for health sciences·2026
Same author

Remote, self-administered, smartphone cognitive testing in a registry-based cohort: Feasibility, reliability, and validity findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Jesús Garcia Castro1, Lídia Vaqué-Alcázar2, Lawren VandeVrede3

  • 1Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Barcelona, Spain.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

利用基于MRI的模型进行参与者选择和结果测量,可显著降低渐进性上核麻 (PSP) 和皮质核退行 (CBD) 临床试验的样本大小要求,提高试验效率.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经退行性疾病 神经退行性疾病
  • 神经成像是一种神经成像.
  • 临床试验设计 临床试验设计

背景情况:

  • 渐进性超核性麻 (PSP) 和皮质核性退行 (CBD) 是严重的神经退行性疾病,缺乏有效的治疗方法和可靠的生物标志物.
  • 临床试验受到PSP和CBD之间重叠的症状和不完美的临床病理相关性所阻碍.
  • 来自MRI的模型已经在预测PSP和CBD病理学方面表现出准确性.

研究的目的:

  • 评估基于MRI的参与者选择和成像结果对PSP和CBD假设临床试验的样本大小估计的影响.
  • 通过结合先进的神经成像技术来确定临床试验设计的效率增长.

主要方法:

  • 利用了来自4个重复多发症神经成像计划 (4RTNI) 的84名参与者的MRI数据,他们被诊断为理查德森综合征 (RS) 或皮质皮质综合征 (CBS).
  • 应用MRI衍生模型来预测PSP,CBD或其他病理,并确定区域缩的MRI签名.
  • 计算了假设试验所需的样本大小,旨在在12个月内检测疾病进展率减少30% (通过MRI签名或PSPRS测量).

主要成果:

  • 磁力共振成像模型预测了PSP,CBD和其他病理,分别在46%,26%和27%的参与者中.
  • 基于MRI的选择和结果减少了PSP试验的样本大小64% (121对336名参与者) 和CBS试验 (160对1301名参与者) 的样本大小.
  • 对于PSP进展的关键MRI标记区域包括中脑和前皮层厚度;对于CBD,中脑/pons体积和前脑/脑内皮层厚度是显著的.

结论:

  • 使用基线MRI进行诊断确定性的参与者选择,加上MRI测量作为试验结果,可以显著提高4R病症的2期临床试验的效率.
  • 这些发现表明,对于PSP和CBD的未来临床试验设计,应该采取更简单的方法.
  • 计划在Davunetide试验队列中进行复制,以验证这些结果.